Solid Bioscience Stock Price, News & Analysis

Solid Biosciences (Nasdaq: SLDB) announced the presentation of three abstracts at the ASGCT 24th Annual Meeting, focusing on AAV vectors and the IGNITE DMD trial for SGT-001, a gene therapy for Duchenne muscular dystrophy. Key presentations include:

• AAV9 immune response mechanisms.
• Characterization of novel AAV vectors for muscle gene delivery.
• 12-month data from the IGNITE DMD Phase I/II trial of SGT-001, scheduled for May 14, 2021.

SGT-001 aims to address the genetic causes of Duchenne by delivering a synthetic dystrophin gene.

Solid Biosciences (Nasdaq: SLDB) announced participation in a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit on April 27, 2021, at 10:30 am ET. Joel Schneider, COO, and Louise Perry, Head of Technical Operations, will discuss advancements in therapies for Duchenne muscular dystrophy.

A live webcast will be available on the Company's investor relations website, and a replay can be accessed afterwards.

Solid Biosciences (Nasdaq: SLDB) announced that Dr. Carl Morris, Chief Scientific Officer, will participate in a panel discussion on Duchenne muscular dystrophy (DMD) at the virtual Guggenheim Healthcare Talks on April 1, 2021, from 9:00 a.m. to 9:50 a.m. EDT. The panel, titled “The more we learn the less we know about DMD,” will explore advancements in DMD therapies. A live webcast of the event will be available on the company’s investor relations website, with a replay accessible afterward.

Solid Biosciences (Nasdaq: SLDB) announced the closing of an underwritten public offering of 25 million shares of common stock at $5.75 each, generating approximately $143.8 million in gross proceeds. This offering included 3.26 million shares from the underwriters' option to purchase additional shares. Jefferies, SVB Leerink, and Piper Sandler were the joint book-running managers for the offering. The shares were issued under an effective shelf registration statement, filed with the SEC on March 13, 2019, and declared effective on March 19, 2019.

Solid Biosciences (Nasdaq: SLDB) has announced the pricing of an underwritten public offering of 21,739,131 shares at $5.75 per share, generating total gross proceeds of $125 million before expenses. An option allows underwriters to purchase an additional 3,260,869 shares. The offering is expected to close on March 23, 2021, subject to customary conditions. Proceeds will fund research and development for SGT-001 and other corporate purposes. The offering involves an effective registration statement filed with the SEC.

Solid Biosciences announced a public offering of $85 million in common stock to enhance funding for its Duchenne muscular dystrophy therapies. The offering is underwritten and includes a 30-day option for underwriters to purchase an additional 15%. Jefferies, SVB Leerink, and Piper Sandler are managing the offering, which is subject to market conditions. The shares are offered under an effective registration statement filed with the SEC. No assurance can be given regarding the offering's completion or its terms due to market uncertainties.

Solid Biosciences Inc. (Nasdaq: SLDB) has reported promising interim data from its IGNITE DMD Phase I/II trial of SGT-001, a gene therapy for Duchenne muscular dystrophy. Data from six patients indicate improvements in functional endpoints, including scores from the North Star Ambulatory Assessment and the 6-Minute Walk Test, with some patients showing a mean improvement in walking distance by over 37 meters. Recent dosing of a seventh patient was successful, with manageable side effects. The next steps involve continued enrollment and evaluation of additional patient outcomes.

Solid Biosciences (Nasdaq: SLDB) announced the grant of an inducement award to its new Chief Legal Officer, Erin Brennan, as approved by independent directors on February 25, 2021. The inducement award consists of an option to purchase 325,000 shares of common stock at an exercise price of $8.52 per share, with a ten-year term and vesting in four equal annual installments. This appointment aims to strengthen the company's leadership in developing therapies for Duchenne muscular dystrophy.

Solid Biosciences (Nasdaq: SLDB) announces key leadership changes aimed at advancing therapies for Duchenne muscular dystrophy. Erin Powers Brennan joins as Chief Legal Officer, while Joel Schneider is promoted to Chief Operating Officer. The company also expands its Board of Directors with the appointments of Clare Kahn and Georgia Keresty, both experienced in the healthcare and pharmaceutical sectors. These moves are expected to enhance the company's strategic direction and operational capabilities in developing its lead gene therapy candidate, SGT-001, and improving patient outcomes.